Input on ICER’s Upcoming Analysis of Erenumab as a Treatment for Migraine
November 29, 2017
IfPA has concerns that ICER is undertaking the cost effectiveness evaluation of Erenumab before sufficient data exists. However, should the evaluation proceed nonetheless, it is imperative that the evaluation incorporate effective estimates for all of the potential benefits associated with more effective treatment of migraine, which include: reduced health care costs associated with treating migraine headaches, reduced health care costs associated with treating the comorbid conditions, increased worker productivity, increased quality of life for patients, increased quality of life for family members or other caregivers, and the potential reduction in costs associated with the opioid abuse crisis.
Categorized in: Analysis